$21.48
+0.98(4.78%)
Mkt Cap $1.2B
$8.71
$21.47
52-Week Range
At a Glance
AI-generatedIntensifying losses and cash burn marked FY2025 for this clinical-stage biotech, driven by R&D ramp for later-stage ficerafusp alfa trials amid no revenue since 2018 inception, buffered by equity financing from common stock sales.
8-K
Bicara Therapeutics reported increased net losses for Q4 and full year 2025, selected an optimal dose for its pivotal Phase 3 trial, and expects its cash to fund operations into the first half of 2029.$1.2B
Market Cap
—
Revenue
-$122M
Net Income
Employees55
Fundamentals
How The Business Makes Money
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0002023658
ISINUS0554771032
CUSIP055477103
Phone617-468-4219
Address116 Huntington Avenue, Boston, MA, 02116, US
SEC EDGAR